117results about How to "High diagnostic value" patented technology

The invention relates to a method for acquiring and evaluating vascular examination data, comprising: acquisition of IVUS images of a vessel to be examined using an IVUS catheter; simultaneous acquisition of angiography data of the IVUS catheter having at least one angiography marker; acquisition of OCT images of the same point of the vessel to be examined using an OCT catheter; simultaneous acquisition of angiography data of the OCT catheter having at least one angiography marker; registering the IVUS and OCT images; determination of contours of the structures of the vessel under examination based on the OCT images; arithmetic histological analysis of the co-registered IVUS and OCT images using the information about the contours; and display the results.

A diagnostic drug and a diagnostic kit for autoimmune diseases including at least one of a polypeptide selected from an HMG-1 family, a polypeptide selected from an HMG-2 family, a fragment thereof which is reactable with an antibody of an autoimmune disease patient, and a method for detecting an antibody of an autoimmune disease patient using the same are provided.

The invention belongs to the biotechnical field and relates to a plasma miRNA marker for diagnosis of lung cancer and application. The invention provides the plasma miRNA marker for diagnosis of lung cancer. The marker comprises miRNA-486, miRNA-150, miRNA-205 and miRNA-210. The invention further provides primer probes shown in sequences SEQ ID NO. 1, SEQ ID NO.2, SEQ ID NO.3 and SEQ ID NO.4 as well as application of the primer probes in preparation of kits for diagnosis of lung cancer. The marker provided by the invention has the beneficial effects that a biomarker which has a relatively high diagnostic value on lung cancer is found, and the biomarker has a relatively high diagnostic value (AUC is 0.975, and the sensitivity and specificity are respectively 90.9% and 100%).

The invention relates to the field of biological detection, particularly to a group of microRNA biological markers for early lung cancer diagnosis and an application thereof. The microRNA biological marker comprises hsa-miR-125a-5p, hsa-miR-193a-5p, hsa-miR-25, hsa-miR-126 and hsa-miR-34a. The serum miRNA biological markers comprising the 5 miRNAs can not only be particularly applied to early lung cancer detection, but also be applied to advanced lung cancer detection.

The invention discloses a liver cancer diagnostic kit based on nucleic acid aptamers, comprises the following ingredients with independent packing: liver cancer nucleic acid aptamer solution, polyacrylamide gel mother liquor, ammonium persulfate, tetramethyl diethylamine, 50% glycerin solution II, 1.25M sodium chloride solution, GelRed dye solution, positive control serum, and negative control serum. The kit has the following characteristics: (1) high diagnostic value, sensitivity of about 85%, specificity of about 85%, and accuracy of about 85%; (2) simpleness and practicality, and only need of conventional vertical electrophoresis and a gel image analysis system to realize the diagnosis; and (3) low cost and high additional value. Liver cancer is one of common malignant tumors in clinic, thus by applying the kit of the invention in clinical application, the consumption is high, the diagnostic level of liver cancer can be effectively raised, good economic benefit and social benefit can be produced, and the application prospect is good.

The invention relates to a method for detecting the content of total alpha-synuclein combined with hemoglobin in erythrocytes of blood. The method comprises the following steps: taking an anti-human hemoglobin monoclonal antibody as a capturing antibody; taking an anti-human alpha-synuclein monoclonal antibody as a detection antibody; and detecting the content of the alpha-synuclein combined with the hemoglobin of Parkinson patients and normal healthy persons by utilizing an antigen-antibody reaction principle, and comparing.

The invention discloses an anti-keratin antibody detection method and an anti-keratin antibody regent box, and belongs to the method for detecting the characteristics of blood in body. The method provided by the invention can be operated as follows: the esophagus of a bandicoot can be made into a biological thin slice which can be taken as an antigen and coated in the reaction region of a piece of slide glass; blood serum to-be-detected is added in the reaction region and then added with complement after the incubation, rinsing and drying in a spanning way, then added with the fluorescent markers of anti-complement antibodies after the incubation, rinsing and drying in a spanning way, and then observed under a fluorescence microscope after the incubation, rinsing and drying in a spanning way; if the horny layer appears typical and regular line-shaped or lamellar fluorescence, the detection result is positive. The regent box provided by the utility model is filled with regents, cover glass and slide glass with biological thin slices, such as negative control serum, positive control serum, condensed phosphate buffer solution and the application solution of the fluorescent markers of complement and anti-complement antibodies. The method provided by the invention is better than the prior method in indicators such as sensitivity, specificity, negative predictive value and positive predicative value, therefore, the method has higher diagnosis value in diagnosing rheumatoid diseases.

An X-ray image processing apparatus includes a site information determination unit configured to determine, based on discrete site information, continuous site information to be obtained by radiographing a moving image, an information acquisition unit configured to extract, from the discrete site information, image construction information, image processing method information, and X-ray exposure control method information, a computation unit configured to compute processing information about a site located between positions represented by the discrete site information using the information extracted by the information acquisition unit, an image processing unit configured to perform image processing based on the processing information which is computed by the computation unit, and an X-ray exposure control unit configured to perform X-ray exposure based on the processing information which is computed by the computation unit.

The invention discloses an exosome miRNA marker of rheumatoid arthritis and a kit and belongs to the technical field of biological detection. According to the exosome miRNA marker of rheumatoid arthritis, an exosome miR-204-5p sequence and a corresponding primer can be used for preparing a rheumatoid arthritis diagnostic kit; very high sensitivity and specificity are realized; and the exosome miRNA marker of the rheumatoid arthritis is beneficial for promoting the developments of early diagnosis, treatment predication and recurrence monitoring of the rheumatoid arthritis in China.

The invention discloses an exosome miRNA marker for early pregnancy diagnosis of sows and application of the exosome miRNA marker. The exosome miRNA molecular marker is prepared from ssc-miR-192, ssc-miR-146a-5p and ssc-miR-149; when the serum exosome miRNA is independently used for diagnosing and distinguishing early pregnant sows and non-pregnant sows, the areas under the ROC curve (AUC) are respectively 0.863, 0.885 and 0.857; the combined AUC of the ssc-miR-192 and the ssc-miR-146a-5p is 0.921; the combined AUC of the ssc-miR-192 and the ssc-miR-149 is 0.902; the combined AUC of the ssc-miR-146a-5p and the ssc-miR-149 is 0.910; when the three miRNAs, namely ssc-miR-192, ssc-miR-146a-5p and ssc-miR-149, are combined, the combined AUC is 0.959; The exosome miRNA molecular marker providedby the invention has high sensitivity and high specificity in early sow pregnancy diagnosis, and has excellent diagnostic performance by combining a plurality of miRNA markers.

The invention discloses seven serum exosome micro-ribonucleic acids (miRNAs) related to diagnosis and treatment of liver cancer, and applications of the seven serum exosome miRNAs. The invention firstly discovers that hsa-miR-122, hsa-miR-125b, hsa-miR-145, hsa-miR-192, hsa-miR-194, hsa-miR-29a and hsa-miR-106a in serum exosomes can be used as biomarkers of the liver cancer, have a higher diagnostic value, provide a rapid and accurate diagnosis way for clinical use, and enable the diagnosis of the liver cancer to be more convenient and easier to implement. The invention also further discoversmatters for inhibiting specific miRNA, and the matters can inhibit the proliferation/growth of cells with the liver cancer, so that a foundation is laid for the clinic treatment of the liver cancer.

The invention relates to an application method for diagnosing an aptamer based on the conventional gel electrophoresis, and belongs to the technical field of the detection and analysis of biomedicine. The application method comprises the following steps of: incubating the aptamer and a blood serum sample, performing the conventional polyacrylamide gel electrophoresis and nucleic acid dyeing, observing a result under an ultraviolet lamp and collecting ultraviolet filtering images, measuring a gray-scale value of a dissociated aptamer strap by gel image analysis software, and analyzing difference between cases and contrast quantitatively to realize quantitative diagnosis. According to the application method, a liver cancer blood serum aptamer is used as a research model to be applied to liver cancer diagnosis, so the sensitivity, specificity and accuracy are up to over 90 percent. The application method is simple, convenient, easy, high in practical value and high in diagnostic efficiency, and has a bright application prospect.

The invention provides a bone marrow smear atypical lymphocyte staining kit and an application method thereof, wherein the kit comprises a reagent tube filled with Polymer Helper, a reagent tube filled with PBS phosphate buffer solution, a reagent tube filled with antigen retrieval buffer, a reagent tube filled with hydrogen dioxide solution, a reagent tube filled with diaminobenzidine staining solution, a reagent tube filled with hematoxylin staining solution, a reagent tube filled with 1% acidulated alcohol, a reagent tube filled with 1% ammonium hydroxide, a reagent tube filled with xylene, a reagent tube filled with ethyl alcohol, a reagent tube filled with CD3 monoclonal antibody, a reagent tube filled with Pax-5 monoclonal antibody and a reagent tube filled with general type CD3 and Pax-5 immunohistochemical antibody and a packing box for separating and centrally packing the reagent tubes. According to the kit and the application method thereof, a bone marrow smear also can be used for carrying out the classification of lymphocyte, the value of bone marrow smear lymphoma diagnosis is greatly improved, and the technology is relatively simple, is easy to popularize and can be used for pathological diagnosis and therapeutic outcome judgment.

The invention discloses an application of serum protein HFREP1 in diagnosis of a rheumatoid arthritis disease state. Disease states of rheumatoid arthritis disease activity scoring systems DAS28 and RA recommended according to European anti-rheumatism alliance are divided into an activity period and a remission period. However, the DAS28 scoring system is a set of subjective scoring system and hashigh requirements for experience of doctors. According to the invention, the serum protein HFREP1 has extremely high diagnostic value in the aspect of diagnosing and distinguishing the active periodand the remission period of rheumatoid arthritis, is high in diagnostic accuracy, is objective and easy to operate compared with the existing DAS28 scoring system, and can be used for preparing a diagnostic kit for diagnosing and distinguishing the active period and the remission period of rheumatoid arthritis.

The invention provides a biomarker for early diagnosis and/or recurrence monitoring of brain glioma and an application of the biomarker, and belongs to the technical field of molecular diagnosis and molecular biology. Research of the invention discovers that the relative expression level of various miRNAs in the cerebrospinal fluid exosome is obviously related to glioma, the number of the miRNAs which are remarkably increased in the cerebrospinal fluid exosome of a glioma patient is 102, the number of the miRNAs which are remarkably decreased in the cerebrospinal fluid exosome of the glioma patient is 167, and the miRNAs and a marker spectrum which is composed of the miRNAs and contains 269 miRNAs have a high diagnosis value. Each of the 269 miRNAs can be independently used as a biomarkerof glioma, a marker spectrum set of the 269 miRNAs has a higher diagnostic value, and a rapid and accurate diagnostic mode is provided for clinic after combined application, so that diagnosis and recurrence detection of glioma are more convenient and easier to implement.

The invention discloses an exosome miRNA marker for early pregnancy diagnosis of ewes and application of the exosome miRNA marker. The exosome miRNA molecular marker comprises oar-miR-22-3p and chi-miR-378-3p. The miRNA molecular marker shows high expression in serum exosomes of ewes in early pregnancy, and when the serum exosome miRNA is independently used for diagnosing and distinguishing the ewes in early pregnancy from the ewes in non-pregnancy, ROC area under the curve (AUC) is 0.891 (0.728, 1.000), 0.922 (0.791, 1.000), respectively; the AUC (95% CI) of the exosome miRNA molecular markeris 0.984 (0.936, 1.000) when early pregnant ewes and non-pregnant ewes are distinguished through combined diagnosis, it can be seen that the exosome miRNA molecular marker has high sensitivity and high specificity in early ewe pregnancy diagnosis, multiple miRNA markers are combined, and superior diagnosis performance is obtained.

In a method and apparatus for optimizing the signal-to-noise ratio (SNR) of a magnetic resonance (MR) dataset acquired by means of a magnetic resonance system having at least one transmit coil, a measurement protocol for an acquisition that is to be performed in order to obtain the MR dataset of a predefined measurement volume. A deviation of an actual flip angle from the predefined flip angle in a specific area of the predefined measurement volume is determined for a preset transmitter scaling. The transmitter scaling of the RF pulse is adjusted in order to correct the actual flip angle so that the actual flip angle is approximated to the predefined flip angle in the specific area. The MR dataset is acquired with the adjusted transmitter scaling.

The invention belongs to the biotechnology field, and discloses a glioma prognostic marker hsa_circ_0021827 and application. In the invention, it is firstly found that the expression level of hsa_circ_0021827 in the serum exosome of a glioma patient is obviously increased compared with a control group (p is equal to 0.025), and ROC analysis shows that the glioma prognostic marker hsa_circ_0021827has a relatively high diagnostic value for a glioma (AUC is equal to 0.823, P is equal to 0.003, the sensitivity is 70% and the specificity is 90.9%). Therefore, an early-stage rapid non-invasive diagnosis of the glioma patient can be made by detecting the expression level of hsa_circ_0021827 in the serum exosome of the glioma patient.